Literature DB >> 2063843

Severe neurologic toxicity induced by cyclosporine A in three renal transplant patients.

B F Palmer1, R D Toto.   

Abstract

Cyclosporine A (CyA) is a potent immunosuppressive agent that is used in organ transplantation and in a variety of immunological diseases. It has a variety of adverse side effects, some of which can be serious and even life-threatening. CyA-associated neurotoxicity is generally mild, consisting of fine tremor. However, more complex neurologic abnormalities, including motor spinal cord and cerebellar syndromes, have rarely been described in bone marrow and liver transplant patients. Renal transplant patients have been spared from such CyA-induced toxicity. In this report, three renal transplant patients are described who developed complex and severe neurologic toxicity in the setting of therapeutic blood levels of CyA, which was completely reversible on discontinuation of the drug. No patient had a prior history of neurological or psychiatric dysfunction and there was no evidence of known psychoactive substance abuse. The toxicity was manifested as flaccid hemiparesis in one and dementia in a second patient. The third patient developed a previously unreported Guillain-Barré-like syndrome consisting of an ascending motor neuropathy. One patient developed reversible lesions involving the cerebral white matter. Whereas similar complex neurologic syndromes have been confined to patients who are intensely immunosuppressed, often debilitated, and have toxic levels of the drug, these three patients serve to emphasize that complex neurotoxicity can occur in stable patients who have therapeutic levels of CyA. Given the use of CyA in an ever-expanding list of disease processes, an appreciation of these potential neurologic syndromes is of paramount importance. At present, CyA-induced neurologic disease remains a diagnosis of exclusion.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2063843     DOI: 10.1016/s0272-6386(12)80300-3

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  5 in total

Review 1.  Progressive multifocal leukoencephalopathy during cyclosporine treatment. A case report.

Authors:  S Gentile; I Sacerdote; D Roccatello; M T Giordana
Journal:  Ital J Neurol Sci       Date:  1996-10

2.  Post-transplant neurotoxicity: what role do calcineurin inhibitors actually play?

Authors:  Evelyn M Sklar
Journal:  AJNR Am J Neuroradiol       Date:  2006-09       Impact factor: 3.825

3.  Novel fluorescence resonance energy transfer-based reporter reveals differential calcineurin activation in neonatal and adult cardiomyocytes.

Authors:  Hojjat Bazzazi; Lingjie Sang; Ivy E Dick; Rosy Joshi-Mukherjee; Wanjun Yang; David T Yue
Journal:  J Physiol       Date:  2015-07-22       Impact factor: 5.182

4.  Guillain Barré syndrome precipitated by the use of antilymphocyte globulin in the treatment of severe aplastic anaemia.

Authors:  B Kaya; C E Davies; H E Oakervee; N C Silver; J Gawler; J D Cavenagh
Journal:  J Clin Pathol       Date:  2005-09       Impact factor: 3.411

Review 5.  Acute leucoencephalopathy during cyclosporin A therapy in a patient with nephrotic syndrome.

Authors:  C Shimizu; S Kimura; Y Yoshida; A Nezu; K Saitoh; H Osaka; Y Aihara; Y Nagasaka
Journal:  Pediatr Nephrol       Date:  1994-08       Impact factor: 3.714

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.